Interest Coverage Ratio: 5.36x
Is the interest coverage ratio high or low?
The interest coverage ratio of 5.36x is 84% below its 4-year average of 34.32x, near the low end of its 4-year range (3.91x–302.50x).
As of Monday, June 29, 2026. 6.13% below its 12-month average of 5.71x.
GEHC Interest Coverage Ratio
Reported quarterly interest coverage; no daily interpolation.
GEHC Average Interest Coverage Ratio Chart
GEHC Current vs Average Interest Coverage Ratio Chart
GEHC Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
5.36x
INTEREST COVERAGE RATIO AVG TTM
5.71x
INTEREST COVERAGE RATIO AVG 3Y
5.20x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.13%
CURRENT VS 3Y AVG
+3.25%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 5.36x | 5.71x | 5.20x | N/A |
| ResMed Inc. (RMD)vs › | $29.05B | 133.66x | 81.27x | 57.81x | 48.16x |
| Zoetis Inc. (ZTS)vs › | $31.88B | 14.80x | 14.41x | 13.27x | 12.34x |
| Biogen Inc. (BIIB)vs › | $31.89B | 7.63x | 8.79x | 9.45x | 11.57x |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 3.14x | 3.21x | 3.42x | 3.19x |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | N/A | N/A | N/A | N/A |
| Centene Corp. (CNC)vs › | $32.44B | -11.24x | 4.28x | 3.30x | 3.63x |
| DexCom, Inc. (DXCM)vs › | $27.07B | 49.83x | 40.70x | 32.97x | 24.93x |
| Medline Inc. (MDLN)vs › | $32.87B | 2.72x | 2.21x | 1.60x | 1.60x |
| Moderna, Inc. (MRNA)vs › | $26.69B | -307.40x | 531.75x | 531.75x | 531.75x |
Financial Health Indicators
Interest Coverage
5.4x
Debt/Equity
0.96
Current Ratio
1.18
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Interest Coverage Ratio FAQ
- What is the interest coverage ratio for GE HealthCare Technologies Inc. (GEHC)?
- The interest coverage ratio for GEHC stock is 5.36x.
- Is GE HealthCare Technologies Inc.'s interest coverage ratio high or low?
- The interest coverage ratio of 5.36x is 84% below its 4-year average of 34.32x, near the low end of its 4-year range (3.91x–302.50x).
- What is the TTM average interest coverage ratio for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average interest coverage ratio for GEHC stock is 5.71x.
- What is the 3Y average interest coverage ratio for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average interest coverage ratio for GEHC stock is 5.20x.
GEHC Interest Coverage Ratio History
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-03-31 | 5.36x |
| 2025-12-31 | 6.45x |
| 2025-09-30 | 5.31x |
| 2025-06-30 | 5.79x |
| 2025-03-31 | 5.67x |
| 2024-12-31 | 7.22x |
| 2024-09-30 | 5.20x |
| 2024-06-30 | 4.64x |
| 2024-03-31 | 3.91x |
| 2023-12-31 | 5.26x |
| 2023-09-30 | 4.47x |
| 2023-06-30 | 4.16x |
| 2023-03-31 | 4.11x |
| 2022-12-31 | 12.95x |
| 2022-09-30 | 302.50x |
| 2022-06-30 | 28.68x |
| 2022-03-31 | 84.83x |
| 2021-12-31 | 121.17x |
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini